

Pietro Sollena MD

CURRICULUM VITAE ET STUDIORUM

Work Address: UOC Dermatologia – Fondazione Universitario Policlinico A. Gemelli
IRCCS - Largo A. Gemelli, n. 8 - 00168 Rome (Italy)

EDUCATION

July - September 2009. Visiting fellow (**Erasmus Program**) at the Department of Dermatology (Chairman: Prof. Paulo Filipe), Hospital Santa Maria, University of Lisbon, Portugal. During this period of time I worked in the field of clinical dermatology.

November 2009. Visiting fellow at the UMHS Department of Dermatology of Ann Arbor, MI 48109 – USA. During this period of time I worked in the field of clinical dermatology and I participated in the “Grand rounds”.

October 2010. Degree in Medicine at the Catholic University of the Sacred Heart of Rome, 110/110 summa cum laude.

2011. Member of the Italian Medical register, n.14524 (PA)

July 2012 – July 2017. Resident in Dermatology and Venereology, at Catholic University of the Sacred Heart of Rome (Chairman: Prof. Ketty Peris).

January 2017 – April 2017. Visiting fellow at the Department of Dermatology (Chairman: Prof. Christiane Querfeld), City of Hope Medical Center, Duarte - Los Angeles, CA. During this period of time I worked in the field of dermato-oncology.

April 2017. EADV course on Mohs' Surgery at the Instituto Valenciano de Oncología (IVO), Valencia – Spain.

July 2017. Dermatologist Certificate at the Catholic University of the Sacred Heart of Rome, 50/50 summa cum laude

January 2018. European board Certificate for medical tumor therapy in Dermato-oncology by EADO (European Association of Dermato-Oncology)

PROFESSIONAL ACTIVITY

I have participated in Phase II-III-IV clinical trials on Dermatologic Inflammatory and Dermato-Oncology diseases since 2009. During the last 10 years I have been deeply

involved in the field of dermatology managing patients with advanced BCC, SCC and Melanoma. I have also a special interest on cutaneous adverse events due to new oncologic treatments. I am a co-founder member of European Network of Cutaneous Adverse Events to Oncologic drugs (ENCADO group founded in June 2019), now included in new EADV task force “Dermatology for cancer patients” (founded in June 2020). I am promoter and co-founder member of Italian task force for diagnosis and treatment of cutaneous adverse events to oncologic drugs (TICURO group founded in May 2022)

Since 2019 reviewer member of Italian Guidelines for management of adverse reaction to Immune-therapy in oncologic patients (AIOM guidelines).

Since 2021, annual invited-professor at university master of Ocular Oncology and Eye tumors at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome.

Actually I work as Dermatologist consultant at Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome.

BOARD MEMBERSHIP

- Società Italiana di Dermatologia e Venereologia (SIDeMaST) since 2012
- European Society of Dermatology and Venereology (EADV) since 2017
- European Association of Dermato-Oncology (EADO) since 2017

SCIENTIFIC PUBLICATIONS

1. De Simone C, Sollena P, Coco V, Caldarola G. Psoriasis and Erythema Nodosum: two comorbidities of inflammatory bowel diseases. *G Ital Dermatol Venereol.* 2013; **148**(2):175-84.
2. Sollena P, Del Regno L, Fagnoli MC, Peris K. Topical and systemic medical treatments of basal cell carcinoma. *G Ital Dermatol Venereol.* 2015; **150**(4):429-34. Epub 2015 Jun 18.
3. Bardazzi F, Amerio P, Amoruso G, et al. Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. Alphard Study Group. *Eur Rev Med Pharmacol Sci.* 2014; **18**(22):3435-52.
4. Caldarola G, Sollena P, Peris K, De Simone C. Human leukocyte antigen-B*58:01 allele in a familial case of Stevens-Johnson syndrome induced by allopurinol. *J Dermatol.* 2015; **42**(7):753-4. doi: 10.1111/1346-8138.12894. Epub 2015 Apr 20.
5. De Simone C, Caldarola G, Maiorino A, Tassone F, Campana I, Sollena P, Peris K. Clinical predictors of non-response to anti TNF alpha agents in psoriasis: a retrospective study. *Dermatol Ther.* 2016 Sep; **29**(5):372-376. doi: 10.1111/dth.12364.
6. Sollena P, Caldarola G, Di Stefani A, Massi G, Peris K. Lichen sclerosus of the glans simulating melanoma. *J Am Acad Dermatol.* 2017 Feb; **76**(2S1):S49-S51. doi: 10.1016/j.jaad.2016.07.015.
7. Garcovich S, Colloca G, Sollena P, Andrea B, Balducci L, Cho WC, Bernabei R, Peris

- K. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. *Aging Dis.* 2017 Oct 1; **8**(5):643-661. doi: 10.14336/AD.2017.0503.
8. Peris K, Alaibac M, Argenziano G, Di Stefani A, et al. Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. *G Ital Dermatol Venereol.* 2018 Dec;**153**(6):747-762. doi: 10.23736/S0392-0488.18.06093-5.
 9. Sollena P, Mannino M, Laurenti L, De Simone C, Peris K. Ibrutinib-associated palmo-plantar fissures in a patient with Chronic Lymphocytic Leukaemia: a novel cutaneous adverse event. *J Eur Acad Dermatol Venereol.* 2019 Apr 16. doi: 10.1111/jdv.15632.
 10. Tagliaferri L, Lancellotta V, Zinicola T, Gentileschi S, Sollena P, Garganese G, Guinot JL, Rembielak A, Soror T, Autorino R, Cammelli S, Gambacorta MA, Aristei C, Valentini V, Kovacs G. Cosmetic assessment in brachytherapy (interventional radiotherapy) for breast cancer: A multidisciplinary review. *Brachytherapy.* 2019 Jun 3. pii: **S1538-4721**(18)30765-7. doi: 10.1016/j.brachy.2019.03.009.
 11. Giulia S, Pietro S, Alessandra V, Maria Concetta F, Carlota G, Alfredo P, Sara T, Luca B, Ketty P. Efficacy and Safety of Vismodegib treatment in patients with Advanced Basal Cell Carcinoma and multiple comorbidities. *Dermatol Ther.* 2019 Oct 12:e13108. doi: 10.1111/dth.13108.
 12. Sollena P, Mannino M, Tassone F, Calegari MA, D'Argento E, Peris K. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. *Drugs Context.* 2019 Nov 6; **8**:212613. doi: 10.7573/dic.212613. eCollection 2019. Review.
 13. Buonsenso D, Cinicola B, Raffaelli F, Sollena P, Iodice F. Social consequences of COVID-19 in a low resource setting in Sierra Leone, West Africa. *Int J Infect Dis.* 2020 Aug;**97**:23-26. doi: 10.1016/j.ijid.2020.05.104. Epub 2020 Jun 1. PMID: 32497794; PMCID: PMC7263219.
 14. Piccerillo A, Fossati B, Cappilli S, Sollena P. Dermatologic surgery in the COVID-19 era: Observations and practical suggestions. *Dermatol Ther.* 2020 Jun 18:e13873. doi: 10.1111/dth.13873. Epub ahead of print. PMID: 32558057; PMCID: PMC7323092.
 15. Moscarella E, Di Brizzi EV, Casari A, De Giorgi V, Di Meo N, Fagnoli MC, Lacarrubba F, Micali G, Pellacani G, Peris K, Piaserico S, Calzavara-Pinton P, Quagliano P, Sollena P, Zalaudek I, Zane C, Argenziano G. Italian expert consensus paper on the management of patients with actinic keratoses. *Dermatol Ther.* 2020 Jul 10:e13992. doi: 10.1111/dth.13992. Epub ahead of print. PMID: 32648324.
 16. Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K; European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. *Breast Cancer Res Treat.* 2020 Sep 10. doi: 10.1007/s10549-020-05914-w. Epub ahead of print. PMID: 32914354.
 17. Sollena P, Cappilli S, Piccerillo A, Chiricozzi A, Peris K. COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission. *Int J Dermatol.* 2020 Sep 24;10.1111/ijd.15208. doi: 10.1111/ijd.15208. Epub ahead of print. PMID: 32970833; PMCID: PMC7537260.
 18. Nikolaou V, Sibaud V, Fattore D, Sollena P, et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. *J Am Acad Dermatol.* 2020 Dec 3:S0190-9622(20)33115-7. doi: 10.1016/j.jaad.2020.08.137.
 19. Buonsenso D, Sollena P, Eke Tchangou M, De Rose C, et al; Black Kids Matter

- Study Group. Black Kids Matter initiative calls for greater inclusion of Black children in clinical trials. *Acta Paediatr.* 2020 Dec 29. doi: 10.1111/apa.15741.
20. Bavetta M, Silvaggio D, Campione E, Sollena P, *et al.* The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. *J Clin Med.* 2021 Jan 26;10(3):466. doi: 10.3390/jcm10030466.
 21. Sollena P, Cappilli S, Federico F, Schinzari G, Tortora G, Peris K. "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. *Hum Vaccin Immunother.* 2021 Mar 24:1-8. doi: 10.1080/21645515.2021.1889449.
 22. Romano M.C., Sollena P. *et al.* Dermocosmetology and breast cancer patients: effectiveness on physical and mental wellbeing. *Aesthetic Medicine/Volume 7/ N°2/April - June 2021*
 23. De Simone C, Mannino M, Sollena P, Deilhes F, Sibaud V, Peris K. Morphea-like changes in the setting of cancer immunotherapy. *J Eur Acad Dermatol Venereol.* 2021 Oct;35(10):e684-e685. doi: 10.1111/jdv.17388.
 24. Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigaros E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement. *J Eur Acad Dermatol Venereol.* 2021 Dec 15. doi: 10.1111/jdv.17855.
 25. Mannino M, Sollena P, Esposito M, Fargnoli MC, Peris K, Nagore E. Self-Assessment Questionnaire on Patient-Physician Concordance on Nevus Self-Count and Models Development to Predict High-Risk Phenotype >50 Nevi. *Dermatology.* 2022 Apr 22:1-10. doi: 10.1159/000523953
 26. Nikolaou V, Apalla Z, Carrera C, Fattore D, Sollena P, *et al.* Clinical associations and classification of immune checkpoint inhibitors-induced cutaneous toxicities: A multicentric study from the EADV-Task Force of Dermatology for Cancer Patients. *Br J Dermatol.* 2022 Jul 21. doi: 10.1111/bjd.21781.
 27. Freites-Martinez A, Nikolaou V, Lallas K, Carrera C, Sollena P, *et al.* Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study. *J Am Acad Dermatol.* 2022 Sep 22:S0190-9622(22)02769-4. doi: 10.1016/j.jaad.2022.08.063.

E-BOOK CHAPTERS

1. Sollena P, Peris K, Carcinoma Basocellulare; "I-derm". e-book 2015. *Link: <http://basalioma.i-derm.it/html/cnt/definizione.asp>*
2. Sollena P, Del Regno L, Peris K. Caso clinico 7; "I-derm". e-book 2015. *Link: <http://basalioma.i-derm.it/html/pag/caso-7-6.asp>*
3. Sollena P, Peris K. EADO - case of the month – September 2016: Kaposi's Sarcoma. *Link: <http://www.eado.org/case-of-the-month/case-of-the-month-september-2016/47>*

CONGRESSES – Oral presentations personally made by doctor Pietro Sollena

November 2015. Speaker at the congress: “La gestione condivisa dermatologo-MMG del paziente psoriasico” - Rome

February 2016. Speaker at the: “Congresso annuale AIDNID: innovazione è condivisione” - Rome

March 2016. Speaker at the AAD 74th Annual Meeting. International Sessions: Italian Symposium. Thursday, March 3, 2016 – Walter E. Convention Center, Washington

May 2016. Speaker at the “91th Congresso Nazionale SIDeMaST” - Genova

December 2016. Speaker at the meeting: “Nuove prospettive terapeutiche per il trattamento del carcinoma basocellulare” - Rome

May 2017. Speaker at the “92th Congresso Nazionale SIDeMaST” - Sorrento

June 2017. Speaker at the 8th Inter-Meeting. Interventional and Metabolic Radiotherapy Multidisciplinary Meeting – Rome

July 2017. Speaker at the “Summer meeting Scuola Dermatologica S.C.” – Rome

September 2017. Speaker at the 26th EADV congress – Geneve

December 2018. Speaker at “Approfondimenti in dermatologia clinica” - Frosinone (RM)

June 2019. Speaker at 24th World Congress of Dermatology – Milan

September 2019. Speaker at the meeting: “Cheratosi attinica, ieri, oggi, domani” – Rome

September 2019. Speaker at the meeting: Corpo ritrovato “Prendersi cura della cura” – Rome

November 2019. Speaker at the meeting: “Terapie e target nei tumori cutanei” – Rome

January 2020. Speaker at the meeting: “Terapia adiuvante nel melanoma” – Rome

September 2020. Speaker at the meeting: “Tumori cutanei non melanoma, fotoprotezione e prevenzione: focus on” – Perugia

November 2020. Speaker at the 29th EADV virtual congress – Vienna

December 2021. Speaker at “Les Journées Dermatologiques de Paris” (JDP) 2021 - Paris

June 2022. Speaker at the “Summer meeting Scuola Dermatologica S.C.” – L’Aquila

September 2022. Speaker at the 31th EADV virtual – Milan

October 2022. Speaker at the meeting: Corpo ritrovato “Noi con voi” – Matera

November 2022. Speaker at the meeting: CML ONE 2022: Cutaneous adverse event to BCR-ABL inhibitors - Barcelona

Rome, 1st February 2023

